Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

20081,564 citationsJournal Articlebronze Open Access

Authors

We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 27, Issue 5, pp. 740-745

Field-Weighted Citation Impact: 44.71